Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Safety Pilot/Phase II, Open-label Study of Varlilumab (CDX-1127) in Combination With Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or Stage IV Melanoma

NCT02413827 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT02413827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02413827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Safety Pilot/Phase II, Open-label Study of Varlilumab (CDX-1127) in Combination With Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or Stage IV Melanoma
Lead sponsor
Celldex Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
April 30, 2015
Completion date
November 9, 2016
Enrollment
9 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable stage iii or stage iv melanoma